TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02566252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: PUL-042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: PUL-042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PUL-042 Inhalation Solution
Description: PUL-042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cromolyn Sodium
Description: Pre-treatment
Study: NCT03475524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic Acid Peeling
Description: Trichloroacetic acid peeling to the three groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trichloroacetic Acid Peeling
Description: Trichloroacetic acid peeling to the three groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: oral tablet 500 mg
Study: NCT02566252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate
Description: Pre-treatment
Study: NCT01828944

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: olive oil
Study: NCT00148356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZoMaxx™ Drug-Eluting Coronary Stent System
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
Description: Drug eluting stent implantation stent in the treatment of coronary artery disease.
Study: NCT02649764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Given IV
Study: NCT00313560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
Study: NCT01595477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Group
Description: Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
Study: NCT00078559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: 30mg intravenous infusion on days 0 (transplant), 1, and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
Study: NCT01828944

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: olive oil
Study: NCT00078559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 2mg orally twice daily, on days 1-60

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
Study: NCT01828944

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Study: NCT02296853

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAF
Description: 25 mg tablet administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: 25 mg tablet administered orally
Study: NCT05484128

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gastrus
Description: Gastrus consisted of a mixture of two human strains of L. Reuteri DSM 17938 and ATCC PTA 6475.~Gastrus will be administered for all the duration of PPI administration (8 weeks) plus two weeks after its discontinuation. A final evaluation will be performed 4 weeks after the discontinuation of both Gastrus.
Study: NCT00078559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (or equivalent)
Description: 250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)/Sulfa (Bactrim, Septra)
Description: 1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valgancyclovir
Description: Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: 400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentamidine
Description: 300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clotrimazole
Description: 10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nystatin
Description: 500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
Study: NCT05484128

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo has an identical preparation to Gastrus
Study: NCT03648762

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Aerobic Exercise Intervention
Description: Aerobic Exercise Intervention - 12 weeks of a minimum of 3 days a week for 60 minutes of aerobic exercise
Study: NCT04265170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BlastX with negative pressure therapy
Description: Blast-X in combination with NPWT on,bacterial bio-burden in pressure ulcers assessed by Fluorescence imaging and quantitative biopsy.
Study: NCT04639401

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: motor entrainment to auditory cues and music during walking on quality of movement
Description: The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: motor entrainment to auditory cues and music during walking on quality of movement
Description: The study contains 1 descriptive and 4 experimental sessions. In the descriptive session, participant's clinical motor and cognitive functions are collected. In the first experimental session, participant's beat perception and synchronisation abilities is examined within a finger tapping paradigm. In the following experimental sessions participants synchronsiation abilities is examined during walking paradigms, to music and metronomes, at different tempi and alignment strategies. In the latter three sessions, apart from outcome measures of synchronization the following will be collected as well: spatio-temporal gait parameters, perceived fatigue, perceived motivation and perceived speed of walking.
Study: NCT02176148

Intervention type: DRUG
Intervention: fluocinonide 0.05% cream
Study: NCT03648762

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Combined Aerobic and Strength Exercise Intervention
Description: Combined Aerobic and Strength Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Combined Aerobic and Strength Exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inspiratory Muscle Training Exercise Intervention
Description: Inspiratory Muscle Training Exercise Intervention- 12 weeks of a minimum of 3 days a week for 60 minutes of Inspiratory Muscle Training Exercise
Study: NCT02168933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 308 nm excimer laser
Description: Biweekly treatments with 308 nm excimer laser for a total of 8 weeks

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: Sham laser treatment to the control side biweekly for a total of 8 weeks.
Study: NCT02101840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apo-Oxycodone CR®
Description: a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyNEO®
Description: a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
Study: NCT01348165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 137882
Description: Powder for oral solution
Study: NCT00506948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: 15 mg/kg by vein or by mouth every 12 hours.
Study: NCT01348165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder for oral solution
Study: NCT00506948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg by vein daily for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion on Day 0.
Study: NCT00728312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
Study: NCT03987919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT00945607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GRT (Guided Relaxation Training)
Description: Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
Study: NCT02753192

Intervention type: OTHER
Group type: OTHER
Intervention: Patients
Description: Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
Study: NCT03143842

Intervention type: DEVICE
Group type: OTHER
Intervention: Vagus Nerve Stimulation
Description: Delivering electrical pulses to the Vagus Nerve
Study: NCT04117789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behavior therapy for depression in adolescents
Description: Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program with therapist support via an internet platform.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-guided internet-delivered cognitive behavior therapy for depression in adolescents
Description: Participants will be assigned to a 10 weeks internet-delivered cognitive behavior therapy program without therapist support via an internet platform.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Participants randomized to TAU, will be referred to the local CAMH's or primary care unit for children and youths and will be free to receive any treatment, either psychosocial, medical or the combination of both.
Study: NCT00925587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
Study: NCT05120206

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).
Description: Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal therapy: motivation and instruction in oral hygiene, debridement using handinstrumentation (Hu-Firedy,Chicago, IL, USA;and American Eagle Instruments,Missoula, MT,USA).
Description: Non-surgical and surgical periodontal therapy in cigarette smokers and non-smokers
Study: NCT03677791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual tour in coronary computed tomography - 360° counselling environment
Description: Virtual tour in coronary computed tomography - 360° counselling environment for CCTA patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current practice
Description: counselling in accordance with current practice: written patient information letter and verbal counselling at the hospital during the CT-examination
Study: NCT01490866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: 5-mg tablets PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg Days 1 and 15; IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m2 Days 1 and 15; IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 Days 1 and 15; IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 Days 1 and 15; IV
Study: NCT01884922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.~Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation.
Study: NCT01558297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: 5 sessions of motivational interviewing over a period of 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: 5 sessions of nutritional counseling over a period of 3 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual with primary care physician
Description: Participants will be encouraged to continue their care with their primary care physician.
Study: NCT03077906

Intervention type: OTHER
Intervention: Medical Files data extraction
Description: Medical Files data extraction

Intervention type: OTHER
Intervention: Medical Files data extraction
Description: Medical Files data extraction
Study: NCT01566864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve clinic based measurement of blood pressure
Description: This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider education system to promote patient-centered care
Description: The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Introduce care management system in clinics
Description: The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
Study: NCT01597219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced intensity haplodentical stem cell transplant
Description: Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 \& +4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myeloablative haploidentical stem cell transplant
Description: Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 \& -2 Stem cell transplant day 0